-
Man City sign Palmeiras winger Allan on five-year deal
-
Putin, Xi, Iran's Pezeshkian in Kyrgyzstan for summit
-
More flooding feared at Grand Canyon after storm leaves 15 missing
-
Fully Permitted Tanzanian Gold Project Clears Path to Construction as Financing, EPCM Fall in Place (LVGLF)
-
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
-
EdWealth Announces MoneyBench Benchmark Comparing AI Money Answers From Ed, ChatGPT and Gemini
-
MEXC Data: BTC Breaks $80,000, Major-Asset Spot Trading Volume Surges 300%
-
Root says new balls behind batsmen's struggles in England
-
G20 finance talks open as US seeks to ramp up pressure on Iran
-
Swollen rivers, washed-out roads hamper Nepal rescue effort
-
Solving Agent Sprawl: The Case for Enterprise Orchestration
-
In France's north, winegrowers bet on a warmer future
-
Springboks switch Kolbe to full-back for third All Blacks Test
-
Deadly virus stalks South Africa's sardines
-
Malaysia's Sarawak eyes cloud seeding as haze worsens
-
South Korea women's football body probes 'period' insult
-
World leaders need to see rising oceans in Pacific: UN official
-
Transitional Fashion Essentials for Autumn: Key Pieces from M&S and Joe Browns
-
Xiaomi Pad 9 Pro Leak Suggests 12.5-Inch Display and Massive Battery
-
China's Xi and Iran's Pezeshkian in Kyrgyzstan, Putin expected
-
UK Homeowners Advised to Use Peppermint Tea Bags to Deter Spiders
-
Rescuers hunt for missing after deadly N.Cyprus ferry accident
-
Nepal toll surges as rescuers struggle through 'unimaginable' disaster
-
Ethiopia's Abiy could consolidate power as 'executive president'
-
Mauled Australian swimmer recalls punching shark
-
Crude prices rise on US-Iran strikes, equities mixed after Warsh remarks
-
Passengers stranded overnight by Kenya airport strike
-
South Korea court gives Unification Church leader 2 years prison
-
Nepal recovers bodies but presses on for trapped tunnel workers
-
US hosts G20 finance talks with growth, Iran pressure on agenda
-
Grand Canyon flash flood leaves one dead, around 15 missing
-
African players in Europe: Wissa flick seals Newcastle victory
-
Venus Williams falls at first hurdle in US Open
-
Venice film preview: Clooney, Oasis and Musk
-
At least five leaders skip annual Pacific Islands summit
-
Poorly Djokovic crashes out of US Open first round
-
I.Coast home-hunters' saga highlights Africa housing crunch
-
Djokovic falls in US Open first round, earliest Grand Slam exit in 20 years
-
At least five leaders to skip annual Pacific Islands summit
-
Chinese guitar capital's stairway to export heaven
-
Latest developments in the US-Iran war
-
Stocks drop as Warsh fans US rate hike bets, crude up on US-Iran strikes
-
Nepal buries dead as rescuers seek thousands missing
-
Injuries cloud tennis as US Open gets under way
-
From Montecito to the Cotswolds: Harry and Meghan eye new UK home
-
Iran retaliates after first US strikes in a month
-
Russia's Putin and China's Xi to attend summit in Kyrgyzstan
-
Itauma says 'I'll be back' after bruising heavyweight title loss
-
John Ternus to lead Apple into the age of AI
-
Brilliant Palou clinches fourth straight IndyCar crown
AstraZeneca says to invest $50 bn in the US
British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington.
A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030.
"Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals," the statement quoted CEO Pascal Soriot as saying.
US President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to his sweeping levies on imports from trading partners.
He ordered an investigation launched into pharmaceutical imports, suggesting that levies could reach up to 200 percent.
The United States is a key market for the pharmaceutical industry, and AstraZeneca had already announced in April that it had begun transferring part of its European production to the United States.
"For decades Americans have been reliant on foreign supply of key pharmaceutical products," US Commerce Secretary Howard Lutnick said in a statement.
He added that the new tariffs are focused on "ending this structural weakness".
The announcement included a new factory in Virginia, which will be the company's "largest single manufacturing investment".
Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have, in recent months, begun shifting investment and production to the United States.
M.O.Allen--AT